Cartesian Therapeutics (RNAC) Capital Expenditures (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Capital Expenditures data on file, last reported at $27000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 97.49% year-over-year to $27000.0 in Q1 2026; TTM through Mar 2026 was $4.4 million, a 129.24% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 543.92% from the prior year.
• Capital Expenditures for Q1 2026 stood at $27000.0, down from $5.3 million in the prior quarter.
• Over the last five years, Capital Expenditures for RNAC reached as high as $5.3 million in Q4 2025 and fell as low as -$1.8 million in Q3 2024.
• Historically, Capital Expenditures has averaged $478562.5 across 5 years, with a median of $77000.0 in 2022.
• On a YoY basis, Capital Expenditures climbed as much as 2769.51% in 2024 and fell as far as 10670.59% in 2024.
• Year by year, Capital Expenditures stood at $1.1 million in 2022, then plunged by 94.03% to $63000.0 in 2023, then soared by 622.22% to $455000.0 in 2024, then jumped by 1074.29% to $5.3 million in 2025, then sank by 99.49% to $27000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $27000.0 in Q1 2026, $5.3 million in Q4 2025, and -$577000.0 in Q3 2025.